Metastatic Hormone Refractory Prostate Cancer-Pipeline Insights, 2016


#515511

60pages

DelveInsight

$ 1250

In Stock

SUMMARY
DelveInsights, Metastatic Hormone Refractory Prostate Cancer-Pipeline Insights, 2016, report provides in depth insights on the pipeline drugs and their development activities around the Metastatic Hormone Refractory Prostate Cancer. The DelveInsightsReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsights Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Metastatic Hormone Refractory Prostate Cancer. DelveInsights Report also assesses the Metastatic Hormone Refractory Prostate Cancer therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Scope